Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$53.76 USD

53.76
22,196,871

+0.86 (1.63%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1

Nektar Therapeutics (NKTR) reported first-quarter 2017 loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents.

    Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up

    Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate

      Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat

      Incyte's first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.

        AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected

        AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2017 loss of 12 cents per share, narrower than the Zacks Consensus Estimate as well as year-ago loss of 13 cents.

          Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates

          Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.

            Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus

            Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.

              Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store?

              Celldex Therapeutics, Inc. (CLDX) is expected to report first-quarter 2017 results on May 4. Celldex's performance has been encouraging with a three-quarter average positive surprise of 8.06%.

                Drug Stocks Q1 Earnings Slated for May 2: MRK, PFE & GILD

                The Q1 earnings season is in full swing with financial results from 288 S&P 500 members or 63.8% of the index already out as of Apr 28, 2017.

                  Company News for April 28, 2017

                  Companies in the News are: F,LUV,UNP,BMY

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More

                    Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.

                      Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View

                      Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.

                        Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY

                        Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.

                          Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?

                          Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.

                            Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?

                            Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.

                              Sweta Killa headshot

                              Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?

                              Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.

                                Arpita Dutt headshot

                                3 Key Factors to Look Out for in Biogen's Q1 Results

                                With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.

                                  Arpita Dutt headshot

                                  Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL

                                  Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.

                                    Is J&J's Pharma Sales Slowdown a Warning for Other Players?

                                    Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.

                                      Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion

                                      Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).

                                        Bristol-Myers and Nordic Ink Biomarker Collaboration Deal

                                        Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies.

                                          5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates

                                          2017 is expected to be a strong year for drug stocks.

                                            Biogen to License Alzheimer Candidate from Bristol-Myers

                                            Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.

                                              J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?

                                              We expect Johnson & Johnson (JNJ), a healthcare bellwether, to beat expectations when it reports first-quarter 2017 results on Apr 18, before the opening bell.

                                                Arpita Dutt headshot

                                                Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops

                                                Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.

                                                  Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo

                                                  Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.